How late after completion of adjuvant capecitabine and radiation would you consider adjuvant olaparib for a patient with gBRCA mutated TNBC?

OlympiA enrolled patients up to 12 weeks post adjuvant chemotherapy. So technically, this patient is within the window, but just barely. For a lower risk patient (e.g. small T1-T2N0, pCR after neoadjuvant therapy), I would probably not consider it one year after completing therapy. However, for a hi...